Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3558 - Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

David Planchard

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

D. Planchard1, P.A. Janne2, H.A. Yu3, D. Moro-Sibilot4, T. Goldberg5, X. Gu6, J. Li5, J. McGill5, C. Yu5, E. Slosberg7

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Medical Oncology, Dana Farber Cancer Institute, Boston/US
  • 3 Medicine, Memorial Sloan Kettering Cancer Center, 10022 - New York/US
  • 4 Thoracic Oncology Unit Shupp, Ptv, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble/FR
  • 5 Clinical Development, Daiichi Sankyo Inc., 07920 - Basking Ridge/US
  • 6 Biostatistics, Daiichi Sankyo Inc., 07920 - Basking Ridge/US
  • 7 Translational Development, Daiichi Sankyo Inc., 07920 - Basking Ridge/US
More

Resources

Abstract 3558

Background

In patients with metastatic EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), resistance to EGFR tyrosine kinase inhibitors (TKIs) arises from the T790M EGFR mutation in over half of cases; up-regulation of “bypass track” activity in non-EGFR signaling pathways is observed in other cases. Up-regulation of expression of the AXL tyrosine kinase has been observed in EGFRm NSCLC patients experiencing disease progression on erlotinib, and xenograft studies have supported the role of AXL inhibition in combination with EGFR TKI treatment in overcoming such resistance. DS-1205c is a novel, orally administered, specific small molecule inhibitor of AXL.

Trial design

This is a multicenter, open-label, Phase 1, dose escalation and dose expansion study of DS-1205c in combination with osimertinib in metastatic or unresectable EGFR-mutant NSCLC subjects experiencing disease progression during treatment with erlotinib, gefitinib, or afatinib, and without T790M resistance mutation; or during treatment with osimertinib. Eligible subjects are at least 18 years of age, have ECOG PS 0 or 1, have radiological documentation of disease progression on erlotinib, gefitinib, afatinib, or osimertinib, and have at least one measurable lesion. This study includes two parts: Dose Escalation and Dose Expansion. In Dose Escalation, subjects receive DS-1205c during a run-in period, followed by combination treatment with DS-1205c and 80 mg daily of osimertinib. Escalation of DS-1205c dosing is guided by the modified Continuous Reassessment Method using a Bayesian logistic regression model following the escalation with overdose control principle. In Dose Expansion, subjects receive DS-1205c at the recommended dose for expansion (RDE) determined in Dose Escalation, in combination with 80 mg daily of osimertinib. Primary objectives are to determine safety, tolerability, and RDE of DS-1205c in combination with osimertinib. Secondary objectives are to assess pharmacokinetic parameters of DS-1205a (free form of DS-1205c), osimertinib, and osimertinib active metabolites, and to assess antitumor activity (RECIST v1.1). Retrospective analysis of AXL expression will be conducted using tumor tissue collected prior to study treatment. Enrollment opened in December 2017.

Clinical trial identification

NCT03255083.

Legal entity responsible for the study

Daiichi Sankyo, Inc.

Funding

Daiichi Sankyo, Inc.

Editorial Acknowledgement

Not applicable

Disclosure

D. Planchard: Advisory boards: AstraZeneca, Boehringer, BMS, Celgene, MSD, Novartis, Pfizer, Roche. P.A. Janne: Consultant: AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmaceuticals, Roche/Genentech, Chugai Pharmaceuticals, Acea Biosciences, Ignyta, Loxo Oncology, Ariad Pharmaceuticals, Eli Lilly Pharmaceuticals, Araxes Pharmaceuticals, Gatekeeper Pharmaceuticals; Research Funding: Astellas Pharmaceuticals, AstraZenenca, Daiichi Sankyo, Puma, Eli Lilly Pharmaceuticals, Boehringer Ingelheim. Patents, Royalties, Other intellectual property: LabCorp. H.A. Yu: Research funding to institution: AstraZeneca, Novartis, Daiichi, Pfizer; Consulting: AstraZeneca. D. Moro-Sibilot: Roche, Abbvie, Eli Lilly, Boehringer, BMS, MSD, Takeda, AstraZeneca. T. Goldberg, J. Li, J. McGill, C. Yu: Employee: Daiichi Sankyo, Inc. X. Gu, E. Slosberg: Employee and stockholder: Daiichi Sankyo.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.